Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Rituximab
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Evidence== *2023, Endothelial dysfunction in ME/CFS patients<ref name="Sandvik2023">{{Cite journal|title=Endothelial dysfunction in ME/CFS patients|date=2023-02-02|url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0280942|journal=PLOS ONE|volume=18|issue=2|pages=e0280942|last=Sandvik|first=Miriam Kristine|last2=Sørland|first2=Kari|last3=Leirgul|first3=Elisabeth|last4=Rekeland|first4=Ingrid Gurvin|last5=Stavland|first5=Christina Særsten|last6=Mella|first6=Olav|last7=Fluge|first7=Øystein|language=en|doi=10.1371/journal.pone.0280942|pmc=PMC9894436|pmid=36730360|issn=1932-6203}}</ref> - [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0280942 (Full text)] ::A substudy showing improvement in post-occlusive reactive hyperemia (PORH) but not Flow-Mediated Dilation (FMD) after 18 months rituximab, no changes in symptoms. *2019, B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.<ref name="phase3-2019">{{Cite journal | last = Fluge | first = Øystein | authorlink = Øystein Fluge | last2 = Rekeland | first2 = Ingrid G. | last3 = Lien | first3 = Katarina | last4 = Thürmer | first4 = Hanne| last5 = Borchgrevink | first5 = Petter C. | last6 = Schäfer | first6 = Christoph | last7 = Sørland | first7 = Kari | last8 = Aßmus | first8 = Jörg | last9 = Ktoridou-Valen | first9 = Irini| date = 2019-04-02 | title = B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial|url=https://www.ncbi.nlm.nih.gov/pubmed/30934066|journal=Annals of Internal Medicine|doi=10.7326/M18-1451|issn=1539-3704|pmid=30934066}}</ref> - [https://www.ncbi.nlm.nih.gov/pubmed/30934066 (Full text)] *2016, Extended [[B cell]] phenotype in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A cross-sectional study<ref name="Mensah, 2016">{{Cite journal | last1 = Mensah | first1 = Fane| authorlink1 = Fane Mensah | last2 = Bansal | first2 = Amolak | authorlink2 = Amolak Bansal | last3 = Berkovitz | first3 = Saul | authorlink3 = Saul Berkovitz | last4 = Sharma | first4 = Arti | authorlink4 = | last5 = Reddy | first5 = Venkat | authorlink5 = Venkat Reddy | last6 = Leandro | first6 = Maria | authorlink6 = Maria Leandro | last7 = Cambridge | first7 = Geraldine | authorlink7 = Geraldine Cambridge | title = Extended B cell phenotype in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A cross-sectional study | journal = Clinical and Experimental Immunology | volume = 184 | issue = 2 | pages = 237-247 | date = 2016 | pmid = | doi = 10.1111/cei.12749 | url = https://academic.oup.com/cei/article/184/2/237/6412161 }}</ref> - [https://onlinelibrary.wiley.com/doi/full/10.1111/cei.12749 (Full Text)] *2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome<ref name="Loebel, 2016">{{Cite journal | last1 = Loebel | first1 = M | authorlink1 = Madlen Loebel | last2 = Grabowski | first2 = P | authorlink2 = Patricia Grabowski | last3 = Heidecke | first3 = H | authorlink3 = | last4 = Bauer | first4 = S | authorlink4 = | last5 = Hanitsch | first5 = LG | authorlink5 = | last6 = Wittke | first6 = K | authorlink6 = | last7 = Meisel | first7 = C | authorlink7 = | last8 = Reinke | first8 = P | authorlink8 = | last9 = Volk | first9 = H | authorlink9 = | last10 = Fluge | first10 = Ø | authorlink10 = Øystein Fluge | last11 = Mella | first11 = O | authorlink11 = Olav Mella | last12 = Scheibenbogen | first12 = C | authorlink12 = Carmen Scheibenbogen | title = Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome | journal = Brain, behavior, and immunity | volume = 52 | issue = | pages = 32-39 | date = 2016 | doi = 10.1016/j.bbi.2015.09.013 | url = https://www.sciencedirect.com/science/article/pii/S0889159115300209?via%3Dihub}}</ref><ref name="SandnesNO">{{citation | author = NRK television, Norway | title = A private clinic in Sandnes, Norway is treating ME with Rituximab | type = video | date = Nov 27, 2015| url = https://www.youtube.com/watch?v=MfqJWRhgVx0 }}</ref> - [https://www.sciencedirect.com/science/article/pii/S0889159115300209 (Full Text)] *2015, B-Lymphocyte Depletion in Myalgic Encephalopathy/Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment<ref name="Fluge2015" /> - [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0129898 (Full text)] *2013, Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls<ref name="Bansal2013">{{Cite journal|title=Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls|date=2013-03-11|url=https://academic.oup.com/cei/article/172/1/73/6421010|journal=Clinical and Experimental Immunology|volume=172|issue=1|pages=73–80|last=Bradley|first=A S|last2=Ford|first2=B|last3=Bansal|first3=A S|language=en|doi=10.1111/cei.12043|pmc=PMC3719933|pmid=23480187|issn=1365-2249}}</ref> - [https://academic.oup.com/cei/article-lookup/doi/10.1111/cei.12043 (Full text)] *2011, Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study<ref name="Fluge2011" /> - [http://www.ncbi.nlm.nih.gov/m/pubmed/22039471/ (Full text)] *2009, Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series<ref name="Fluge2009">{{Cite journal|title=Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series|date=2009-07-01|url=https://doi.org/10.1186/1471-2377-9-28|journal=BMC Neurology|volume=9|issue=1|pages=28|last=Fluge|first=Øystein|last2=Mella|first2=Olav|doi=10.1186/1471-2377-9-28|pmc=PMC2711959|pmid=19566965|issn=1471-2377}}</ref> - [https://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-9-28 (Full text)]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs